JPMorgan analyst Anne Samuel said Health Catalyst put up a "solid" report in its first quarter since coming public and gave fiscal year guidance that was in line with her model. Management noted that the midpoint of Q3 revenue guidance is above modeled expectations as part of the company's IPO process and Samuel said increased transparency from the public offering was helpful in driving conversations with prospective customers, making its pipeline supportive of the second half guidance. Samuel, who continues to see significant runway for growth for Health Catalyst, keeps an Overweight rating on the shares.